4 Analysts Have This to Say About Haemonetics
Portfolio Pulse from Benzinga Insights
In the last quarter, Haemonetics (NYSE:HAE) received three somewhat bullish ratings and one indifferent rating from analysts. The average price target for the stock is $109.0, compared to its current price of $91.585, implying an upside. The average price target has increased by 7.13% over the past month.
August 09, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics received mostly bullish ratings from analysts, with an average price target of $109.0, indicating potential upside from its current price.
The bullish ratings and higher price target suggest that analysts are positive about Haemonetics' future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100